The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Abstract Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating a clinical challenge. Therefore, it i...
Main Authors: | Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-11-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12902-021-00900-9 |
Similar Items
-
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01) -
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
by: Yunzhi Zou, et al.
Published: (2021-11-01) -
Prolactinomas: evolution after menopause
by: Maria Susana Mallea-Gil, et al. -
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
by: Xiangming Cai, et al.
Published: (2022-04-01) -
Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01)